Clinical trial
Study Of 323U66 SR In Major Depressive Disorder
NCT00135512 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00135512 |
|---|---|
| Title | Study Of 323U66 SR In Major Depressive Disorder |
| Official title | An Open-Label, Multi-Center, Phase II Study Evaluating the Safety and Efficacy of 323U66 SR in Patients With Depression |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Depressive Disorder |
| Intervention type | Drug |
| Interventions | bupropion hydrochloride |
| Enrollment | 234 |
| Start date | Dec 1, 2004 |
| Primary completion | May 28, 2007 |
| Completion | May 28, 2007 |
| First posted | Aug 26, 2005 |
| Last update posted | Feb 1, 2019 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: